Ioana Grigoras

Prof. Ioana Grigoras

Grigore T Popa University of Medicine and Pharmacy Iasi, Romania
+1
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
EKEva Kirmeier
Eva Kirmeier
LELars I Eriksson
Lars I Eriksson
HLHeidrun Lewald
Heidrun Lewald
MFMalin Jonsson Fagerlund
Malin Jonsson Fagerlund
AHAndreas Hoeft
Andreas Hoeft
DZDarja Zupanĕiĕ
Darja Zupanĕiĕ

1 January 2018 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
TAT.E.F. Abbott
T.E.F. Abbott
AFA.J. Fowler
A.J. Fowler
MCM.S. Chew
M.S. Chew
RPRupert M. Pearse
Rupert M. Pearse
SBScott Beattie
Scott Beattie
TWTroy Wildes
Troy Wildes

1 April 2018 in Journal of Critical Care Medicine
Verified
Journal Article
Open access
PDF file
ODOlguța Diaconu
Olguța Diaconu
ISIanis Siriopol
Ianis Siriopol
LPLaura Iulia Poloșanu
Laura Iulia Poloșanu
Ioana GrigorasIoana Grigoras
Ioana Grigoras
Ventilator-associated pneumonia (VAP) is a common and serious nosocomial infection in mechanically ventilated patients and results in high mortality, prolonged intensive care unit- (ICU) and hospital-length of stay and increased costs. In order to reduce its incidence, it is imperative to better understand the involved mechanisms and to identify the source of infection. The role of the endotracheal tube (ET) in VAP pathogenesis became more prominent over the last decades, along with extensive research dedicated to medical device-related infections and biofilms. ET biofilm formation is an early and constant process in intubated patients. New data regarding its temporal dynamics, composition, germ identification and consequences enhance knowledge about VAP occurrence, microbiology, treatment response and recurrence. This paper presents a structured analysis of the medical literature to date, in order to outline the role of ET biofilm in VAP pathogenesis and to review recommended methods to identify ET biofilm microorganisms and to prevent or decrease VAP incidence.

1 August 2017 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
TAT. Ahmad
T. Ahmad
ARAnca Ristescu
Anca Ristescu
Ioana GrigorasIoana Grigoras
Ioana Grigoras
CACesar Aldecoa
Cesar Aldecoa
CHC. Hofer
C. Hofer
RPR.M. Pearse
R.M. Pearse
The incidence and impact of postoperative complications are poorly described. Failure-to-rescue, the rate of death following complications, is an important quality measure for perioperative care but has not been investigated across multiple health care systems. We analysed data collected during the International Surgical Outcomes Study, an international 7-day cohort study of adults undergoing elective inpatient surgery. Hospitals were ranked by quintiles according to surgical procedural volume (Q1 lowest to Q5 highest). For each quintile we assessed in-hospital complications rates, mortality, and failure-to-rescue. We repeated this analysis ranking hospitals by risk-adjusted complication rates (Q1 lowest to Q5 highest). A total of 44 814 patients from 474 hospitals in 27 low-, middle-, and high-income countries were available for analysis. Of these, 7508 (17%) developed one or more postoperative complication, with 207 deaths in hospital (0.5%), giving an overall failure-to-rescue rate of 2.8%. When hospitals were ranked in quintiles by procedural volume, we identified a three-fold variation in mortality (Q1: 0.6% vs Q5: 0.2%) and a two-fold variation in failure-to-rescue (Q1: 3.6% vs Q5: 1.7%). Ranking hospitals in quintiles by risk-adjusted complication rate further confirmed the presence of important variations in failure-to-rescue, indicating differences between hospitals in the risk of death among patients after they develop complications. Comparison of failure-to-rescue rates across health care systems suggests the presence of preventable postoperative deaths. Using such metrics, developing nations could benefit from a data-driven approach to quality improvement, which has proved effective in high-income countries.

15 January 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
MEMark R Edwards
Mark R Edwards
GFGordon Forbes
Gordon Forbes
NMNeil MacDonald
Neil MacDonald
VBVladislav Berdunov
Vladislav Berdunov
BMBorislava Mihaylova
Borislava Mihaylova
RPRupert M Pearse
Rupert M Pearse
Introduction Postoperative morbidity and mortality in older patients with comorbidities undergoing gastrointestinal surgery are a major burden on healthcare systems. Infections after surgery are common in such patients, prolonging hospitalisation and reducing postoperative short-term and long-term survival. Optimal management of perioperative intravenous fluids and inotropic drugs may reduce infection rates and improve outcomes from surgery. Previous small trials of cardiac-output-guided haemodynamic therapy algorithms suggested a modest reduction in postoperative morbidity. A large definitive trial is needed to confirm or refute this and inform widespread clinical practice. Methods The Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial is a multicentre, international, parallel group, open, randomised controlled trial. 2502 high-risk patients undergoing major elective gastrointestinal surgery will be randomly allocated in a 1:1 ratio using minimisation to minimally invasive cardiac output monitoring to guide protocolised administration of intravenous fluid combined with low-dose inotrope infusion, or usual care. The trial intervention will be carried out during and for 4 hours after surgery. The primary outcome is postoperative infection of Clavien-Dindo grade II or higher within 30 days of randomisation. Participants and those delivering the intervention will not be blinded to treatment allocation; however, outcome assessors will be blinded when feasible. Participant recruitment started in January 2017 and is scheduled to last 3 years, within 50 hospitals worldwide. Ethics/dissemination The OPTIMISE II trial has been approved by the UK National Research Ethics Service and has been approved by responsible ethics committees in all participating countries. The findings will be disseminated through publication in a widely accessible peer-reviewed scientific journal. Trial registration number ISRCTN39653756.

1 July 2012 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
MRM. Ruhnke
M. Ruhnke
José-Artur PaivaJosé-Artur Paiva
José-Artur Paiva
WMW. Meersseman
W. Meersseman
JPJ. Pachl
J. Pachl
Ioana GrigorasIoana Grigoras
Ioana Grigoras
MKM. Kantecki
M. Kantecki
Clin Microbiol Infect 2012; 18: 680687 Abstract A prospective, multicentre, phase IIIb study with an exploratory, open-label design was conducted to evaluate efficacy and safety of anidulafungin for the treatment of candidaemia/invasive candidiasis (C/IC) in specific ICU patient populations. Adult ICU patients with confirmed C/IC meeting =1 of the following criteria were enrolled: post-abdominal surgery, solid tumour, renal/hepatic insufficiency, solid organ transplant, neutropaenia, and age =65 years. Patients received anidulafungin (200 mg on day 1, 100 mg/day thereafter) for 1042 days, optionally followed by oral voriconazole/fluconazole. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Secondary endpoints included global response at the end of intravenous therapy (EOIVT) and at 2 and 6 weeks post-EOT, survival at day 90, and incidence of adverse events (AEs). The primary efficacy analysis was performed in the modified intent-to-treat (MITT) population, excluding unknown/missing responses. The safety and MITT populations consisted of 216 and 170 patients, respectively. The most common pathogens were Candida albicans (55.9%), C. glabrata (14.7%) and C. parapsilosis (10.0%). Global success was 69.5% (107/154; 95% CI, 61.676.6) at EOT, 70.7% (111/157) at EOIVT, 60.2% (77/128) at 2 weeks post-EOT, and 50.5% (55/109) at 6 weeks post-EOT. When unknown/missing responses were included as failures, the respective success rates were 62.9%, 65.3%, 45.3% and 32.4%. Survival at day 90 was 53.8%. Treatment-related AEs occurred in 33/216 (15.3%) patients, four (1.9%) of whom had serious AEs. Anidulafungin was effective, safe and well tolerated for the treatment of C/IC in selected groups of ICU patients.